Introduction Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story 6-month HIV PrEP makes coverage gains ...
HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...
GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect ...
A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...
A new study of the longest-acting form of injectable PrEP, lenacapavir, has shown no adverse interactions with hormone therapy for trans women and men. Marketed under the brand name Yeztugo by Gilead ...
ATLANTA — A study from Emory University, published in the Journal of the American Medical Association, confirms that MISTR’s telehealth model is transforming HIV prevention in the U.S. Nearly one in ...
The World Health Organization (WHO) has called for access expansion to newly approved human immunodeficiency virus (HIV) medication amid “sharp and sudden” global funding cuts. This year has been a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results